Managing Director

Pranay Godha (DIN 00016525): Managing Director

Prashant Godha (DIN 00012759)

Executive Director

Anand T. Kusre (DIN 00818477)

Independent Director

Dr. (Mrs.) Manisha Premnath (DIN 05280048)

Independent Director

Kamal Kishore Seth ( DIN 00194986)

Independent Director

Dr. Narendra Mairpady (DIN 00536905)

Independent Director

Corporate Management team

Premchand Godha

Executive

Managing Director of the Company for a period of 5 years commencing 11th November, 2023 on the terms

and conditions including remuneration as approved by the Nomination and Remuneration Committee of the Board and as set out in

the agreement dated 29th May, 2023 entered into between the Company and Mr. Pranay Godha, which agreement be and is hereby

specifically approved with liberty to the Board (which includes a duly constituted Committee of the Board) to alter and vary the terms

and conditions of his appointment, including remuneration (within the overall limits specified under Section 197 of the Act), as it may

deem fit, and in such manner as may be agreed to between the Board and Mr. Pranay Godha.

RESOLVED FURTHER THAT the Board of Directors be and is hereby authorised to do all such acts, matters, deeds and things and to take

such steps as expedient or desirable to give effect to this resolution”.

6.

To consider and, if thought fit, to pass, the following resolution as a Special Resolution:

“RESOLVED THAT in supersession of all the earlier resolution(s) passed in this regard and pursuant to the provisions of Section 62(1)

(b) and all other applicable provisions, if any, of the Companies Act, 2013 (“the Act”) and read with Rule 12 of the Companies (Share

Capital and Debentures) Rules, 2014, the Memorandum and Articles of Association of the Company and statutory modification(s) or

re-enactment of the Act for the time being in force and the provisions of the Securities and Exchange Board of India (Share Based

Employee Benefits and Sweat Equity) Regulations, 2021 including any modifications thereof or supplements thereto (“the Regulations”

/ “SEBI SBEB Regulations”), and subject to such approvals, consents, permissions and sanctions as may be necessary and subject to such

conditions and modifications as may be prescribed and imposed while granting such approvals, consents, permissions and sanctions

which may be agreed to by the Board of Directors of the Company (hereinafter referred to as “the Board” which term shall be deemed to

include the Nomination and Remuneration Committee of the Board), the approval and consent of the members of the Company be and

is hereby accorded to the “Ipca Laboratories Ltd. - Employees Stock Option Scheme 2023” (“Ipca ESOS 2023”/“Scheme”) and to the Board

to create, offer and grant, from time to time, upto 50,74,084 Employee Stock Options, being not exceeding 2% of the paid-up Equity

Share Capital of the Company, at any point of time, that could be granted to the eligible employees and whole-time/executive directors

of the Company, as determined in terms of Ipca ESOS 2023, from time to time, in one or more tranches, each such option granted would

be exercisable on conversion into one equity share of the face value of Re. 1/- each fully paid-up of the Company, on payment of the

requisite exercise price to the Company, and on such other terms and conditions as may be determined by the Board in accordance with

the provisions of the scheme and provisions of applicable laws as may be prevailing at the relevant time.

RESOLVED FURTHER THAT the equity shares so issued and allotted from time to time in accordance with Ipca ESOS 2023 as mentioned

hereinbefore shall rank pari-passu in all respect with the then existing equity shares of the Company.

NOTICE:

letter to the Company or upload on the VC portal / e-voting portal.

j.

Pursuant to the provisions of Section 108 of the Act read with Rule 20 of the Companies (Management and Administration) Rules,

2014 (as amended), Secretarial Standard on General Meetings (SS-2) issued by the Institute of Company Secretaries of India (“ICSI”)

and Regulation 44 of Listing Regulations read with circulars issued by MCA and SEBI in this regard, the Company is providing

remote e-Voting facility to its Members in respect of the business to be transacted at the 73rd AGM and facility for those Members

participating in the 73rd AGM to cast vote through e-Voting system during the 73rd AGM.

k.

AGM has been convened through VC/OAVM in compliance with applicable provisions of the Companies Act, 2013 read with

circulars issued by MCA and SEBI from time to time.:

letter etc. with attested specimen signature of the duly authorized signatory(ies) who are authorized to

vote, to the Scrutinizer by e-mail to scrtunizer@ipca.com with a copy marked to evoting@nsdl.co.in. Institutional shareholders (i.e. other

than individuals, HUF, NRI etc.) can also upload their Board Resolution / Power of Attorney / Authority: Letter etc. by clicking on “Upload

Board Resolution / Authority Letter” displayed under “e-Voting” tab in their login.

2.

It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.

Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will

letter mentioning your folio number,

name, complete address, email address to be registered along with scanned self attested copy of the PAN and any document

(such as Driving Licence, Passport, Bank Statement, AADHAR) supporting the registered address of the Member, by email to the

Company’s email address investors@ipca.com

b.

For the Members holding shares in demat form, please update your email address through your respective Depository Participant/s.

15. The Notice of the 73rd AGM and the Annual Report for the financial year 2022-23 including therein, inter-alia, the Audited Standalone

and Consolidated Financial Statements for the financial year ended 31st March, 2023, will be available on the website of the Company

at www.ipca.com and the website of BSE Limited at www.bseindia.com and The National Stock Exchange of India Ltd. at www.nseindia.

com.

The Notice of 73rd AGM will also be available on the website of NSDL at www.evoting.nsdl.com.

16. Members are requested to:

(a)

intimate to the Company / their Depository Participant (“DP”), changes, if any, in their registered address at an early date;

(b)

quote their Registered Folio No. and/or DP Identity and Client Identity number in their correspondence;:

Managing Director of the Company for a further period of 5 (five)

years with effect from 11th November, 2023. Accordingly, an agreement setting out the terms and conditions of his re-appointment including

remuneration payable to him was entered into between the Company and Mr. Pranay Godha,: Managing

Managing Director will be based on certain performance criteria to be laid down by the Board and will be payable annually

after annual accounts have been adopted by the shareholders.

c)

Perquisites: In addition to the salary and commission, the: Managing

Managing Director to officers and employees of the Company for the purpose of business of the

Company shall not be deemed to be contravention of this clause.

11. Any property of the company or relating to the business of the Company, including memoranda, notes, records, reports, plates, sketches,

plans, recorded diskettes, drives, tapes, electronic memory gadgets or other documents which may be in the possession of or under the

control of the: Managing Director or to which the Managing Director has at any time access shall, at the time of the termination of his

employment be delivered by the Managing Director to the Company or as it shall direct and the Managing Director shall not be entitled

to the copyright in any such document which he hereby acknowledges to be vested in the Company or its assigns and binds himself not

to retain copies of any of them.

12. The Company may forthwith terminate the employment, if the Managing Director shall at anytime be permanently prevented by ill-

health or accident from performing his duties.

13. The Company shall be entitled to forthwith terminate the agreement if he becomes insolvent or makes any composition or arrangement

with his creditors or he ceases to be a Director of the Company.

14. If the Managing Director is guilty of inattention to or negligence in the conduct of the business or of any other act or omission inconsistent

with his duties as the Managing Director or of any breach of this Agreement which in the opinion of the Board renders his retirement

from the office of Managing Director desirable, the Company by not less than thirty days notice in writing to the Managing Director

determine this Agreement and upon the expiration of such notice, the Managing Director shall cease to be the Director of the Company.

15. Notwithstanding anything to the contrary contained in the Agreement, either party shall be entitled to terminate the Agreement, at

anytime by giving to the other party 60 days notice in writing in that behalf, without the necessity of showing any cause, and on the

expiry of the period of such notice, this Agreement shall stand determined and the Managing Director shall cease to be the Director of

the Company. Provided that the aforesaid notice may be waived mutually by the parties hereto.

16. The terms and conditions including the remuneration payable to the Managing Director for the said appointment and/or this Agreement

may be altered and varied, from time to time, by the Board as it may, in its discretion, deem fit.

17. This Agreement represents the entire agreement, between the parties hereto on the subject matter thereof.

Except Mr. Pranay Godha, appointee himself, his father Mr. Premchand Godha, Executive

Managing Director of the Company with effect from 1st April, 2023 for the

remainder period of his current tenure of appointment till 20th August, 2024.

iii.

Mr. Pranay Godha was re-designated/appointed as the: Managing

Managing Director of the Company for a further period of 5 years with effect from 11th

November, 2023. This re-appointment is subject to the approval of the shareholders at the ensuing Annual General Meeting.

During the year under report:

Mr. M. R. Chandurkar, Promoter of the Company who was also the Director/: Managing Director of the Company for nearly four decades from

1975 expired on 20th June, 2022. The Company has immensely benefited from the services rendered by him during his tenure as a Director/

Managing Director of the Company.

Mr. Dev Parkash Yadava, an Independent Director of the Company expired on 2nd August, 2022. Mr. Yadava was the Independent Director of

the Company since April 2012. The Company has immensely benefited from his knowledge of pharma industry and guidance / advice given

by him during his tenure as an Independent Director all these years.

The Board places on record its sincere appreciation for the services rendered by them during their tenure as Directors of the Company.

None of the directors of the Company are debarred from holding the office of Director by virtue of any SEBI order or order by any other

competent authority.

In the opinion of the Board, the independent directors possess appropriate balance of skills, experience and knowledge, as required.

A brief note on Directors retiring by rotation and eligible for re-appointment is furnished in the Report on Corporate Governance annexed

herewith.

KEY MANAGERIAL PERSONNEL

During the financial year under report, the following persons continue to be the Key Managerial Personnel of the Company:

Mr. Premchand Godha

-

Managing Director / CEO is given at the end of the Corporate Governance Report.

WHISTLE BLOWER POLICY / VIGIL MECHANISM

There is a Whistle Blower Policy in the Company and that no personnel have been denied access to the Chairman of the Audit Committee. The

policy provides for adequate safeguards against victimization of persons who use vigil mechanism. The Whistle Blower Policy is posted on the

website of the Company www.ipca.com.

PREVENTION OF INSIDER TRADING

The Company has also adopted a code of conduct for prevention of insider trading. All the Directors, senior management employees and

other employees who have access to the unpublished price sensitive information of the Company are governed by this code. During the year

under Report, there has been due compliance with the said code of conduct for prevention of insider trading.:

Managing Director/CFO, one promoter: Managing Director/CEO and one promoter Executive Director

and four non-executive independent directors including one woman director comprising of at least one half of the total strength

of the Board with independent judgment in the deliberation and decision of the Board. The

Managing Director of the Company with effect from 1st April, 2023 for

the remainder period of his current tenure of appointment till 20th August, 2024.

•

Mr. Pranay Godha was re-designated/appointed as the: Managing Director and CEO of the Company with effect from 1st April,

2023 for the remainder period of his current tenure of appointment till 10th November, 2023.

The necessary special/ordinary resolutions in this regard was approved by the shareholders vide a postal ballot conducted by the

Company.

c)

Number of other companies in which Director is a Director and committees in which the Director is Member or Chairperson

Name of Director

No. of other companies

in which Director

(including private and

Section 8 companies)

No. of Committees in

which Member

(other than Ipca)

No. of Committees

of which

Managing Director and Mr. Prashant Godha, Executive Director are

related to each other. None of the other Directors are related to each other.

f)

Number of shares and convertible instruments held by Non-Executive Directors

The information about number of shares held by Non-Executive Directors in the Company is given in the table above. None of the

Non-Executive Directors currently hold any convertible instruments of the Company.

g)

Web link where details of familiarisation programmes imparted to independent directors is disclosed

The Company has conducted familiarisation programmes for the Independent Directors with regards to their role, rights and

responsibilities as Independent Directors. The Independent Directors are also regularly briefed on the nature of the pharmaceutical

industry and the Company’s business model. The familiarisation programs have been uploaded on the website of the Company at

https://www.ipca.com/wp-content/pdf/familiarisation-programmes-imparted-to-independent-directors-2022-23.pdf).

h)

A chart or a matrix setting out the skills/expertise/competence of the board of directors

The Board considers that the following core skills / expertise / competence of the Board of Directors are required in the context of

its business and its sector for it to function effectively: Research & development, technical, manufacturing, marketing, commercial,

regulatory, finance, legal and general management.

In the opinion of the Board, these skills / expertise / competence are actually available with its Board of Directors.

Skills / Expertise / Competence of the Board of Directors that

are required in the context of business of the Company

Names of the Directors who have such skills / expertise /

competence

Research & Development

Mr. Premchand Godha

Mr. A. K. Jain

Mr. Pranay Godha

Mr. Anand T. Kusre

Dr. (Ms.) Manisha Premnath

Technical

Mr. Pranay Godha

Mr. Anand T. Kusre

Dr. (Ms.) Manisha Premnath

Manufacturing & Marketing

Mr. Premchand Godha

Mr. A. K. Jain

Mr. Pranay Godha

Mr. Prashant Godha

Dr. (Ms.) Manisha Premnath

Commercial

Mr. Premchand Godha

Mr. A. K. Jain

Mr. Kamal Kishore Seth

Dr. Narendra Mairpady:

Managing Director in-charge of Finance/CFO and Mr. Pranay Godha,: Managing

Managing Director, Joint: Managing Director and Executive Directors for the

Financial Year 2022-23 are given below:

(`)

Name of Directors

Salary*

Benefits /

Perquisites /

Pension etc.*

Commission

(performance

linked)

Stock

Options

Total

Mr. Premchand Godha (

Managing Director / CFO as well as to the Audit

Committee.

13. The disclosures of the compliance with corporate governance requirements specified in regulation 17 to 27 and clauses (b) to

(i) and (t) of sub-regulation (2) of regulation 46

a)

The Company has a process to provide, inter-alia, the information to the Board as specified in Part A of Schedule II of the SEBI (Listing

Obligations and Disclosure Requirements) Regulations, 2015 pertaining to Corporate Governance. The Board also periodically

reviews the compliances by the Company of all applicable laws.

b)

The Board of Directors in their meeting regularly discuss and are satisfied that the Company has plans in place for orderly succession

for appointment to the Board of Directors and Senior Management.

c)

Code of Conduct for Board and Senior Managerial Personnel

The Board has laid down a code of conduct for Board members and senior management personnel of the Company. The code

incorporates the duties of independent directors as laid down in the Companies Act, 2013. The said code of conduct is posted on

Company’s website www.ipca.com.

The Board members and senior management personnel have affirmed compliance with the said code of conduct. A declaration in

this regard signed by the: Managing

Managing Director/CFO, Mr. Pranay Godha,: Managing

Managing Director and Mr. Prashant Godha, Executive

Director are related to each other. He is not related to any other Director or Key Managerial Personnel (KMP) of the Company.

During the financial year 2022-23 he has attended all the 6 (six) board meetings held by the Company.

He has not retired/resigned as a Director of any listed company in the past 3 years.

(ii)

Mr. Premchand Godha (DIN 00012691)

Mr. Premchand Godha aged 76 years is a qualified Chartered Accountant and a Commerce graduate. He is also a first

generation entrepreneur. He is also a Promoter of the Company. He has over 47 years of experience in the pharmaceutical

industry. He acquired the Company along with others in the year 1975 and has been managing the day to day business affairs

of the Company since then.

He is the Director/: Managing Director of the Company since 31st October, 1975 and has been the

Managing Director and Mr. Prashant Godha, Executive

Director are related to each other. He is not related to any other Director or Key Managerial Personnel (KMP) of the Company.

He has not retired/resigned as a Director of any listed company in the past 3 years.

Being re-appointed as the: Managing Director

(i)

Mr. Pranay Godha (DIN 00016525)

Mr. Pranay Godha, aged 51 years has done his B.Sc. from University of Bombay and has also obtained a degree in M.B.A

from the New York Institute of Technology, USA. He has over 2 decades of experience in the field of Marketing and General

Management.

Mr. Pranay Godha was appointed as the Business Development Manager of the Company w.e.f 16th April, 2003 and was

subsequently promoted as Vice President - Generics Business of the Company w.e.f. 1st November, 2004. He was further

promoted as President – Generics Business of the Company in May, 2006 and subsequently appointed as the Executive

Director of the Company with effect from 11th November, 2008. He was re-designated as the Managing Director/CEO of the

Company w.e.f. 1st April, 2023 for the remainder period of his current tenure of appointment.

He holds 17,00,990 equity shares (0.67%) of the Company.

He holds Directorship in the following companies:

1.

Kaygee Laboratories Pvt. Ltd.

2.

Mexin Medicaments Pvt. Ltd.

3.

Kaygee Investments Pvt. Ltd.

4.

Paschim Chemicals Pvt. Ltd.

He is also Director of some of the foreign subsidiaries of the Company where he represents the Company as a Director.

He is not a member of any Committee of the Board in other companies in which he is a Director.

Mr. Pranay Godha is not debarred from holding the office of Director by virtue of any SEBI order or order by any other

competent authority.

Number of Board Meetings held and attended by him during his tenure as Director of the Company is given in the Report on

Corporate Governance of the respective financial year annexed with the Company’s Annual Reports which are available on

the Company’s website www.ipca.com.

Mr. Premchand Godha, Executive

Managing Director / CEO

CEO/CFO CERTIFICATION

The Board of Directors

Ipca Laboratories Limited

48, Kandivli Industrial Estate,

Kandivli - West

Mumbai – 400 067

We hereby certify that:

(a)

We have reviewed financial statements and the cash flow statement for the year ended 31st March, 2023 and that to the best of our

knowledge and belief;

i.

these statements do not contain any materially untrue statement or omit any material fact or contain statements that might be

misleading; and

ii.

these statements together present a true and fair view of the Company’s affairs and are in compliance with existing accounting

standards, applicable laws and regulations.

(b)

No transaction is entered into by the Company during the year which is fraudulent, illegal or violative of the Company’s code of conduct.

(c)

We accept responsibility for establishing and maintaining internal controls for financial reporting and that we have evaluated the

effectiveness of the internal control systems of the Company pertaining to financial reporting and we have disclosed to the Auditors

and the Audit Committee, deficiencies in the design or operation of such internal controls, if any, of which we are aware and the steps

we have taken or propose to take to rectify these deficiencies.

(d)

We have indicated to the Auditors and the Audit Committee:

i.

significant changes in internal control over financial reporting during the year;

ii.

significant changes in accounting policies during the year and that the same have been disclosed in the notes to the financial

statements; and

iii.

instances of significant fraud of which we have become aware and the involvement therein, if any, of the management or an

employee having a significant role in the Company’s internal control system over financial reporting.

Mumbai

29th May, 2023

For Ipca Laboratories Ltd.

Pranay Godha: Managing

Managing Director

2

2

3.

Mr. Ajit Kumar Jain

Joint: Managing Director

2

2

4.

Mr. Prashant Godha

Executive Director

2

2

5.

Mr. Dev Parkash Yadava

(expired 02.08.2022)

Independent Director and

Managing Director/CEO)

11,26,52,160

6.46%

310.66

2.

Mr. A. K .Jain

(Joint: Managing Director/CFO)

7,75,40,552

9.64%

213.83

3.

Mr. Pranay Godha

(Executive Director)

5,09,76,382

10.07%

140.58

4.

Mr. Prashant Godha

(Executive Director)

4,60,00,532

22.43%

126.85

5.

Mr. A. T. Kusre

(Independent Director)

10,50,000

(12.5%)

2.90

6.

Dr. Manisha Premnath

(Independent Director)

9,50,000

(9.52%)

2.62

7.

Mr. Kamal Kishore Seth

(Independent Director)

14,00,000

(6.67%)

3.86

8.

Dr. Narendra Mairpady

(Independent Director)

(Appointed w.e.f. 20.10.2022)

6,00,000

-

1.65

9.

Mr. Dev Parkash Yadava

(Independent Director)

(Expired on 2.08 2022)

2,50,000

-

0.69

10.

Mr. Harish P. Kamath

(Corporate Counsel & Company Secretary)

1,54,82,993

11.08%

42.70

ii.

The median remuneration of the employees of the Company during the financial year was ` 3,62,624/-.

iii.

In the financial year, there was an increase of 6.15% in the median remuneration of employees.

iv.

There were 16,167 permanent employees on the rolls of Company as on March 31, 2023.

v.

Average percentage increase made in the salaries of employees other than the managerial personnel in the financial year 2022-23 was

8.6% whereas there is an increase of 9.82% in the managerial remuneration for the same financial year.

vi.

It is hereby affirmed that the remuneration paid is as per the Remuneration Policy for Directors, Key Managerial Personnel and other

Employees.

Mumbai, 29th May, 2023

For and on behalf of the Board

Premchand Godha

Executive

Managing Director)

022-6210 6020

ajit.jain@ipca.com

13

Reporting Boundary

Standalone

II

Products and Services

14

Details of business activities (accounting for 90% of the turnover):

Sr.

No.

Description of Main Activity

Description of Business Activity

% of Turnover of the entity

1

Manufacture of Pharmaceuticals

Development, Manufacturing and

Marketing of Pharmaceuticals Products

100%

15

Products/Services sold by the entity (accounting for 90% of the entity’s Turnover):

Sr.

No.

Product

NIC Code

% of Turnover of the entity

1

Manufacture of Pharmaceuticals

21002

100%

III

Operations

16

Number of locations where plants and/or operations/offices of the entity are situated

Location

Number of plants

Number of offices

Total

National

18

5

23

International

2

5

7

17

Markets served by the entity

A

Number of locations

Locations

Total

National (No. of States)

Pan-India

International (No. of Countries)

More than 100

B

What is the contribution of exports as a percentage of the total turnover of the entity?

Over 44.61% of the company’s total revenue ( standalone ) can be attributed to its earning from exports.

C

A brief on types of customers

Our customers include wholesalers, distributors, pharmacy chains, hospitals, government institutions and other

pharmaceutical companies.:

Managing Director

9

Does the entity have a specified

committee of the Board/ Director

responsible for decision making on

sustainability related issues? (Yes /

No). If yes, provide details.

Yes.

The ESG steering committee is responsible for decision making on sustainability related

issues. It is chaired by the: Managing

letter of even date which is annexed as Annexure A and Forms an integral part of this report.:

letter.

1.

Maintenance of secretarial record is the responsibility of the management of the Company. Our responsibility is to express an opinion

on these secretarial records based on our audit.

2.

We have followed the audit practices and process as were appropriate to obtain reasonable assurance about the correctness of the

contents of the secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records.

We believe that the process and practices, we followed provide a reasonable basis for our opinion.

3.

We have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.

4.

Where ever required, we have obtained the Management Representation about the Compliance of laws, rules and regulations and

happening of events etc.

5.

The Compliance of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of

management. Our examination was limited to the verification of procedure on test basis.

6.

The Secretarial Audit report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with

which the management has conducted the affairs of the Company.

Place: Mumbai

Date: 29.05.2023

For Parikh & Associates

Company Secretaries

Jigyasa N. Ved

Partner

FCS No: 6488 CP No: 6018

UDIN: F006488E000405084

PR No.: 1129/2021:

Managing Director and CFO (DIN 00012657)

Pranay Godha

N. Jayendran: Managing

Managing Director and CFO (DIN 00012657)

Pranay Godha

N. Jayendran: Managing

Managing Director and CFO (DIN 00012657)

Pranay Godha

N. Jayendran: Managing

Managing Director and CFO (DIN 00012657)

Pranay Godha

N. Jayendran: Managing

letter, the security shall be

created within 6 months from the date first disbursement.

Satisfaction of charges

As per the records of the Registrar of Companies, Maharashtra, available on their website, various charges are yet to be satisfied,

however, as per records of the Company, such loans have been fully repaid and none of the lenders have communicated or

demanded any outstanding amount from the Company. The summarized details are as under::

Managing Director (Executive

Chairman w.e.f. April 1, 2023)

India

Mr. Ajit Kumar Jain

Joint: Managing

Letter of Credit opened by

bankers.

31.59

80.13

31.59

80.13

Total

2,032.20

187.74:

Managing Director and CFO (DIN 00012657)

Pranay Godha

N. Jayendran: Managing

Managing Director and CFO (DIN 00012657)

Pranay Godha

N. Jayendran: Managing

Managing Director and CFO (DIN 00012657)

Pranay Godha

N. Jayendran: Managing

Managing Director and CFO (DIN 00012657)

Pranay Godha

N. Jayendran: Managing

Managing Director and CFO (DIN 00012657)

Pranay Godha

N. Jayendran: Managing

letter, the security shall be

created within 6 month from the date first disbursement.

Satisfaction of charges

As per the records of the Registrar of Companies, Maharashtra, available on their website, various charges are yet to be satisfied,

however, as per records of the Company, such loans have been fully repaid and none of the lenders have communicated or

demanded any outstanding amount from the Company. The summarised details are as under:

No. of Cases

Aggregate Amount

(`Crores)

Period range

Reason

20

58.15

1961-2005

Old cases-Records not available/being taken up with lenders.

8

42.26

1972-2010

Necessary form filed, however, ROC records not updated.

g)

Reconciliation of cash flows from financing activities as per Ind AS 7

(` Crores)

Particulars

Lease liabilities

Interest

Long term

borrowings

Short term

borrowings

Balance as on April 1, 2021

13.05

0.17

9.13

243.21

Interest accrued

1.28

5.62

-

-

Changes from financing cash flows

(7.16)

(4.90)

346.98

193.34

Exchange (gain) / loss

-

-

0.60

(2.14)

Acquisition through Business Combination

0.58

-

-

-

Addition during the year

8.23

-

-

-

Transfer within categories

-

-

38.47

(38.35)

Non cash changes

-

-

-

-

Closing balance as on March 31, 2022

15.98

0.89

395.18

396.06

Interest accrued

1.65

42.80

-

-

Changes from financing cash flows

(9.16)

(39.83)

363.44

294.27

Exchange (gain) / loss

(0.05)

-

8.84

(0.26)

Addition during the year

15.32

-

-

-

Transfer within categories

-

-

(115.68)

115.68

Non cash changes

-

-

-

-

Closing balance as on March 31, 2023

23.74

3.86

651.78

805.75:

Managing Director (Executive

Chairman w.e.f. April 1, 2023)

India

Mr. Ajit Kumar Jain

Joint: Managing

Letter of Credit opened by

bankers.

31.59

80.13

31.59

80.13

Total

2,032.20

204.36:

Managing Director and CFO (DIN 00012657)

Pranay Godha

N. Jayendran: Managing

Managing Director and CFO (DIN 00012657)

Pranay Godha: Managing

Managing Director and CFO (DIN 00012657)

Pranay Godha: Managing

